Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 420-424

  Itoh, Tatsuya ^a   Itagaki, Shirou ^b   Sumi, Yoshinobu ^b   Hirano, Takeshi ^b   Takemoto, Isao ^a   Iseki, Ken ^b  

^a Sapporo Social Insurance General Hospital   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Baicalin; Caco 2 cells; Diarrhea; Irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BAICALIN; BROMSULFOPHTHALEIN; DRUG METABOLITE; GREPAFLOXACIN; IRINOTECAN; PRAVASTATIN; PROBENECID;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; INTESTINE CELL; LOW TEMPERATURE PROCEDURES; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CAMPTOTHECIN; COLORING AGENTS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; INTESTINES; SULFOBROMOPHTHALEIN; TUMOR CELLS, CULTURED;

EID: 17644374513     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0937-4     Document Type: Article

References (23)

1. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan (CPT-Il) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449
2. Akimoto K, Kawai A, Ohya K (1994) Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull 42:2135-2138
3. Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159-1169
4. Enerson BE, Drewes LR (2003) Molecular features, regulation, and function of monocarboxylate transporters: implications for drug delivery. J Pharm Sci 92:1531-1544
5. Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749
6. Horikawa M, Kato Y, Sugiyama Y (2002) Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm Res 19:1345-1353
7. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MS, Mathieu-Boue A, Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10- hydroxycamptothecin. Cancer Res 53:2823-2829
8. Itagaki S, Sugawara M, Kobayashi M, Miyazaki K, Iseki K (2003) Mechanism of active secretion of phenolsulfonphthalein in the liver via MRP2 (abcc2), an organic anion transporter. Drug Metab Pharmacokinet 18:238-244
9. Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K (2004) Pharmacokinetic modulation of irinotecan metabolites by sulfobromophthalein. J Pharm Pharmacol 56:809-812
10. Itoh T, Takemoto I, Itagaki S, Sasaki K, Hirano T, Iseki K (2004) Biliary excretion of irinotecan and its metabolites. J Pharm Pharm Sci 7:13-18
11. Katsura T, Inui KI (2003) Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation. Drug Metab Pharmacokinet 18:1-15
12. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703-708
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
14. Mizuno N, Sugiyama Y (2002) Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet 17:93-108
15. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T (1993) Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5-10
16. Rivory LP, Bowles MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111
17. Sakata Y, Suzuki H, Kamataki T (1994) Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11). Jpn J Cancer Chemother 21:1241-1244
18. Satoh H, Ishikawa H, Murakami O, Yamashita Y, Maeno T, Kamma H, Ohtsuka M, Hasegawa S (1999) Reduction by hange-shashin-to (TJ-14), a herbal medicine on gastrointestinal tract complications induced by CPT-11 containing chemotherapy. Cancer Res Ther Control 7:321-323
19. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Prospective effect of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978-984
20. Takasuna K, Hagiwara T, Hirohashi M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of b-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752-3757
21. Tamai I, Takanaga H, Maeda H, Sai Y, Ogihara T, Higashida H, Tsuji A (1995) Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids. Biochem Biophys Res Commun 214:482-489
22. Tsuji A (2002) Transporter-mediated drug interactions. Drug Metab Pharmacokinet 17:253-274
23. Yamaguchi H, Yano I, Saito H, Inui K (2001) Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2. Eur J Pharmacol 431:297-303